Altris AI Advanced Flagging System

Altris AI, a vendor-neutral, web-based AI decision support platform for optical coherence tomography (OCT) analysis, has introduced an advanced flagging system designed to search through large volumes of OCT scans, including historical data.

The new functionality enables clinicians to search their entire patient databases within minutes to identify OCT scans with specific retina pathologies or biomarkers from a comprehensive list of over 70 conditions. This will be particularly useful to identify suitable candidates as new therapeutic options for eye diseases become available.

For specialists working with geographic atrophy (GA) biomarkers, for example, the system has capabilities to exclude the presence of GA biomarkers in 1, 3, and 6 mm zones as defined by the Early Treatment Diabetic Retinopathy Study (ETDRS), facilitating early pathology development detection.

In a statement, Altris said the flagging system works across large datasets, including OCT scans from different imaging devices, ensuring a high degree of precision and interoperability.

“Flags are a clinical shortcut. Instead of manually searching through thousands of scans, you can now filter precisely for what you need – whether that’s subretinal fluid, GA progression, or early glaucoma indicators. It’s about making the data work for you,” explained Professor Maria Znamenska, Chief Medical Officer at Altris AI and a practising ophthalmologist in the United States.

The new flagging feature is designed to enable eye care professionals to:

• Track risk-related biomarkers and set reminders for timely patient follow-ups,
• Identify clinical study candidates within minutes by scanning large historical datasets,
• Support new treatment adoption by pinpointing patients who match eligibility criteria, and
• Study rare or complex cases by filtering unique pathology and biomarker combinations for deeper clinical insights.

“Flags make it possible to build patient cohorts in minutes,” Dr Znamenska added. “Whether it’s for research or introducing a new therapy, you now have a reliable tool to search for the right patients efficiently.”
 

 *Altris biomarkers